From the Glycobiology Program, Cancer Research Center, the Burnham Institute, La Jolla, California 92037
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() |
---|
Mucin-type O-glycans are classified
according to their core structures. Among them, cores 2 and 4 are
important for having N-acetyllactosamine side chains, which
can be further modified to express various functional oligosaccharides.
Previously, we discovered by cloning cDNAs that the core 2 branching enzyme, termed core 2 Mucin-type glycoproteins are unique in having clusters of large
numbers of O-glycans. These O-glycans contain
N-acetylgalactosamine residues at reducing ends, which are
linked to serine or threonine in a polypeptide (1). These
attached O-glycans can be classified into several
different groups according to the core structures (2). In many
cells, core 1, Gal Those sialyl Lex and sulfated sialyl Lex in
O-glycans have been shown to be preferential ligands for P-
and L-selectin (6-10). It has been also shown that
poly-N-acetyllactosamines can be extended from core 2 branches (3, 5, 7, 11, 12). Poly-N-acetyllactosamines provide the backbone for additional modifications such as sialyl Lex. Moreover, a linear poly-N-acetyllactosamine
(Gal In the gastrointestinal tract, oligosaccharides with core 3, GlcNAc To understand the roles of these oligosaccharides in normal and
pathological conditions, it is essential to understand the regulation
of their biosynthesis. To this end, we previously cloned cDNAs
encoding C2GnT (termed in the present study C2GnT-leukocyte type
(C2GnT-L)) from human HL-60 promyelocytic cells (22) and IGnT from
human PA-1 embryonic carcinoma cells (23). C2GnT-L and IGnT share
homologous sequences in three regions of their catalytic domains (23).
Neither C2GnT-L nor IGnT, however, forms core 4 structure. On the other
hand, a C2GnT purified from mucin-producing cells, termed C2GnT-mucin
(C2GnT-M) type, was reported to contain C2GnT and C4GnT activities in
the same enzyme (2, 15, 16). In the present study we describe the
isolation of cDNA encoding such an enzyme using EST sequence, which
has strong homology with C2GnT-L and IGnT. We found that this newly
cloned enzyme is unique in having C2GnT activity as well as core 4 and
I branching activities. We termed this new enzyme C2GnT-M, because it
is mainly expressed in mucin-producing tissues.
Isolation of cDNA Encoding C2GnT-M--
The coding sequences
of human C2GnT and IGnT homologous region A (nucleotides 315-702 for
C2GnT-L and nucleotides 252-618 for IGnT; Refs. 22 and 23) were used
to search dbEST using the TBLASTN program. A single query gene
(AA307800) of 554 base pairs was found to have 67 and 62% identity
with the coding regions of C2GnT and IGnT, respectively. Judging from
the nucleotide sequence, the EST clone AA307800 did not encompass the
whole coding sequence. Using the primers based on the sequence of this EST clone and human fetal brain Marathon Ready cDNA
(CLONTECH) as a template, PCR resulted in a product
of the expected sequence of 247 base pairs.
Human fetal brain Marathon Ready cDNA was then used as a template
to obtain both the 5'- and 3'- sequence. 5' RACE and 3' RACE were
separately carried out by PCR using antisense primer or sense primer
and AP1 adapter (CLONTECH). Antisense and sense primers used were CCL2AS (5'-CCAGCTTACTGGCTATGAAGACATTTGG-3') and CCL1
(5'-GAGCACTTCAAGGCTGAAAGGAAGTTC-3'). These primers were designed to
have a 247-base pairs overlapping sequence between these two RACE
products. PCR products were cloned into pCR2.1-TOPO (Invitrogen), and
colony hybridization was performed to identify the RACE products using
a 32P-labeled DNA fragment of 247 base pairs, obtained by
PCR using CCL1 and CCL2AS primers described above. The nucleotide
sequence was identical among several clones examined. Based on the
obtained sequences, a cDNA was prepared by reverse
transcription-PCR of poly(A)+ RNA from HT-29 colonic
carcinoma cells, and the sequence of genomic DNA was analyzed by PCR.
Reverse transcription-PCR was carried out as described previously (24),
except that Thermoscript (Life Technologies) was used. Because two
nucleotide sequences were found to be identical, the cDNA obtained
by the above reverse transcription-PCR was thus cloned into
pcDNA3.1/Zeo( Construction of Vector Encoding a Chimeric C2GnT-M--
The
cDNA fragment encoding a putative catalytic domain plus stem region
was prepared by PCR using pcDNA3.1-C2GnT-M as a template. The 5'
primer for the PCR contained the sequence of BglII site and
nucleotides 99-124 (nucleotides 1-3 encode the initiation methionine), whereas the 3' primer contained the 3' end of the coding
sequence, stop codon, and XbaI site. The cDNA fragment encoding amino acid residues 34-438 of C2GnT-M was ligated into BamHI and XbaI sites of pcDNA3-A harboring a
cDNA encoding a signal peptide and IgG binding domain of protein A
(24), resulting in pcDNA3-A·C2GnT-M. Similarly, the catalytic
domain of IGnT (amino acid residues 30-400) was cloned into
pcDNAI-A (24), resulting in pcDNAI-A·IGnT.
pcDNAI-A·C2GnT-L was constructed exactly as described before
(22), except that pcDNAI-A described recently (24) was used.
Enzyme Assays--
pcDNA3-A·C2GnT-M,
pcDNAI-A·C2GnT-L, or pcDNAI-A·IGnT was transiently
transfected into CHO cells as described previously (25). Twenty-four h
after the transfection, the medium was replaced with serum-free
Opti-MEM (Life Technologies) and cultured for an additional 48 h.
The spent medium obtained was then concentrated by Centriprep 30 (Amicon) and directly used for C2GnT-L and IGnT assay. For assaying
C2GnT-M, the chimeric enzyme was adsorbed to IgG-Sepharose from the
concentrated spent medium, and the enzyme bound to IgG-Sepharose was
used as the enzyme source as described before (26). The enzyme
incubation mixture contained 1 mM acceptor, 100 mM GlcNAc, 50 mM D-galactonic acid
CHO cells transfected with pcDNAI-A vector was used as a negative
control, and the radioactivity obtained was subtracted from the
radioactivity obtained in experiments with the enzyme. Because CHO
cells contain no C2GnT or IGnT activity (22, 23, 28, 29), the
radioactivity obtained in mock experiments was <0.1% of the
radioactivity incorporated in the reactions with the highest incorporation.
As acceptors, Gal
To identify the reaction products, the product, obtained after C18
reversed phase column chromatography, was subjected to high performance
liquid chromatography using a column (4 × 300 mm) of
NH2-bonded silica (Varian Micropak AX-5) equipped in Gilson 306. The column was eluted for 35 min with a linear gradient from the
solvent A to a mixture of solvent A (70%) and solvent B (30%); solvent A was composed of 80% acetonitrile and 20% 15 mM
KH2PO4 in H2O, whereas solvent B
was composed of 40% acetonitrile and 60% 15 mM
KH2PO4 in H2O.
Expression of C2GnT-L, C2GnT-M, and IGnT in CHO Cells--
CHO
cells were transiently transfected with pcDNAI-C2GnT-L,
pcDNA3.1-C2GnT-M, or pcDNAI-IGnT, and the expression of core 2 branched oligosaccharides and I antigen was detected by T305 antibody and anti-I serum (Ma), respectively, as described previously (22, 23).
For expression of core 2 branched oligosaccharides, CHO cells were
cotransfected with pcDSR Northern Blot Analysis--
Northern blots of multiple human
tissues and cancer cell lines (CLONTECH) were
hybridized with 32P-labeled cDNA fragments of
pcDNAI-C2GnT-L and pcDNA3.1-C2GnT-M, as described previously
(25). The cDNA fragments were prepared by BamHI and
PstI digestion (nucleotides Chromosomal Mapping--
DNA samples were prepared from a panel
of human × rodent somatic cell hybrids containing human
minichromosomes from 83 radiation hybrids of the Stanford Human Genome
Center G3 RH panel (31, 32) (Research Genetics, Huntsville, AL). To
determine the C2GnT-M locus, these DNA samples were analyzed
by PCR using 5' primer (5'-TCAGGGGTCACCCGAGGGGACCAAG-3'; nucleotides
211-235) and 3' primer (5'-CTCCACCTCTTCTTTGCTCAGTGG-3'; nucleotides
367-390). The PCR conditions were 10 cycles of 94 °C for 1 min,
60 °C for 1 min, and 72 °C for 30 s followed by 25 cycles of
94 °C for 1 min, 63 °C for 1 min, and 72 °C for 30 s.
The maximum likelihood analysis was carried out by submitting the
results to the RH server at the Stanford Genome Center and NCBI GeneMAP
`98 (http://www.ncbi.nlm.nih.gov/genemap/), as described previously
(31, 32). Similarly, chromosomal mapping was carried out on the C2GnT-L
and IGnT genes using PCR and the Stanford Human Genome Center G3 RH
panel. It was also obtained using 3'-EST mapping data from the National
Center for Biotechnology Information.
Isolation of cDNA Encoding C2GnT-M--
Comparison of cloned
C2GnT and IGnT demonstrated that there are three regions highly shared
by these two members of the
The full-length cDNA obtained encodes an open reading frame of 1314 base pairs, predicting a protein of 438 amino acid residues (50,863 Da), which we subsequently termed C2GnT-M (Fig.
1). A hydropathy plot predicts that this
protein has a type II membrane topology seen for almost all mammalian
glycosyltransferases so far cloned (33). The amino acid sequence of
C2GnT-M has 48.2 and 33.8% identity with that of C2GnT-L and IGnT,
respectively, indicating that newly cloned C2GnT-M is related more
closely to C2GnT-L than to IGnT (Fig. 2).
In particular, the amino acid sequence of C2GnT-M is highly homologous
to that of C2GnT-L in three regions in the catalytic domain; both share
72.1, 57.7, and 75.0% identity in A, B, and C regions, respectively
(Fig. 2). No other cDNA in the data base has a significant
similarity with C2GnT-M.
There are two potential N-glycosylation sites (Fig. 1,
asterisks) in the C2GnT-M sequence. A consensus sequence for
polyadenylation signal is present in nucleotides 1747-1752 followed by
a poly(A) tail (Fig. 1). Judging from the size of the mRNA (see
below), the cDNA (2128 base pairs) mostly covers the whole transcript.
C2GnT-M Directs the Expression of Core 2 Branched Oligosaccharides
and I Antigens on the Cell Surface--
Because C2GnT-M is highly
homologous to C2GnT-L and IGnT, we tested whether C2GnT-M can direct
the expression of core 2 branched oligosaccharides and I antigen on the
cell surface. After transfecting with C2GnT-L or C2GnT-M together with
a leukosialin cDNA, CHO cells showed strong staining with T305
antibody, which reacts with core 2 oligosaccharides on leukosialin
(Fig. 3). In contrast, no staining was
observed when CHO cells were transfected with pcDNAI-IGnT under the
same conditions (Fig. 3, upper right). On the other hand,
CHO cells were moderately and strongly stained with anti-I antibody
after transfecting with pcDNA3.1-C2GnT-M and pcDNAI-IGnT,
respectively (Fig. 3). The I antigen was not, however, expressed after
transfecting C2GnT-L (Fig. 3, lower left). These results
indicate that C2GnT-M has a unique property in having the activities of
both core 2 and I branching enzymes.
C2GnT-M Has Core 2, Core 4, and I Branching Enzyme
Activities--
Previously it has been shown that a partially purified
preparation of C2GnT from bovine lung trachea contained the activities of C4GnT, C2GnT, and IGnT (16). Because our newly cloned enzyme has
both the C2GnT and IGnT activities, we tested whether the cloned enzyme
may be related to the enzyme previously described.
As shown in Fig. 4A, C2GnT-L
exhibited a strong activity toward Gal
The recombinant IGnT exhibited strong activity as a cIGnT, as shown
previously (34), but also moderate activity as a dIGnT and very weak
activity as a C4GnT (Fig. 3C).
Expression of C2GnT Transcripts in Various Human Tissues and Cancer
Cell Lines--
Northern blot analysis demonstrates that transcripts
of C2GnT-M are expressed predominantly in colon, small intestine,
trachea, stomach, and thyroid and are barely expressed in testis,
prostate, kidney, and pancreas (Fig. 5).
The transcripts of C2GnT-L, on the other hand, are more widely
expressed and were detected also in heart, brain, placenta, spleen,
peripheral leukocytes, lymph node, and bone marrow, where the
transcripts of C2GnT-M were not detected (Fig. 5). Moreover, the
transcripts of C2GnT-L were detected in HL-60, MOLT-4, and Raji
leukemic cell lines, colon adenocarcinoma SW480, and cervical carcinoma
HeLa cells, where the transcripts of C2GnT-M were not detected. On the
other hand, the C2GnT-M transcripts were detected in A549 lung
carcinoma cell line, where the C2GnT-L transcripts were not detected
(Fig. 5, far right). These results indicate that C2GnT-M and
C2GnT-L are differentially expressed in different tissues.
Chomosomal Mapping of the C2GnT-M Gene--
To determine the
chromosomal localization of the C2GnT-M gene, PCR analysis was carried
out using the Stanford G3 RH panel. This analysis placed the C2GnT-M
gene between two chromosome markers, D15S1160 and D15S1347, thus
mapping the gene to q22.1 region of chromosome 15. Similar analysis
placed the C2GnT-L gene and IGnT gene at q13 of chromosome 9 and at p24
of chromosome 6, respectively.
In the present study, we have isolated a cDNA encoding a novel
C2GnT, C2GnT-M. C2GnT-M is unique in catalyzing more than one enzymatic
reaction, forming core 4 branches and I branches in addition to core 2 branches. Previously, fucosyltransferase III and ST3Gal III, an
C2GnT-M is almost exclusively expressed in small and large intestines,
trachea, stomach, and thyroid among tissues examined (Fig. 5), thus
likely involved in the synthesis of mucin-type oligosaccharides.
Accordingly, we termed this new enzyme C2GnT-M (mucin-type). It is not
apparent why the C2GnT-M is also expressed in thyroid. However, it was
recently demonstrated that a major glycoprotein in calf thyroid
contains core 2 branched O-glycans and I-branched
N-glycans (38), indicating that thyroid synthesizes mucin-type O-glycans.
It is noteworthy that C2GnT-M exhibits a significant activity of C4GnT.
This finding is consistent with previous reports that the presence of
C4GnT activity is always associated with the presence of C2GnT activity
when various mucin-producing tissues were examined (15, 16, 19, 20). It
is very likely that C2GnT-M is responsible for C4GnT activity in these
tissues. C2GnT-L, on the other hand, lacks C4GnT activity (Fig. 4). In
small intestine, colon, and stomach, significant amounts of the
transcripts for C2GnT-L and C2GnT-M were detected (Fig. 5), suggesting
that both enzymes contribute to the C2GnT activity in these tissues. In
fact, recent studies on C2GnT-L knock-out mice demonstrated that a
residual C2GnT activity exists in small and large intestines among
tissues examined after C2GnT-L is inactivated (39). It is most likely
that C2GnT-M cloned in the present study is responsible for this activity.
C2GnT-M is also unique in transferring a GlcNAc residue preferentially
to predistal galactose residues of GlcNAc The results obtained in the present study reveal that the genes of
C2GnT-M, C2GnT-L, and IGnT are located in chromosome 15, q22,
chromosome 9, q13, and chromosome 6, p24, respectively. The chromosomal
mapping of C2GnT-L and IGnT genes was corroborated by a recent report
using the Genebridge 4 RH panel, which was developed independently from
the Stanford G3 RH panel (40). The gene locus for IGnT was originally
reported to be in chromosome 9, q21 (23). The reason for this
discrepancy in the IGnT chromosomal mapping is not clear but may be
related to a more sensitive method used in the present study. Similar
to the results obtained in the present study, the genes for two highly
related polysialyltransferases, PST and STX, were located at different
chromosomes by fluorescence in situ hybridization (41).
These results, as a whole, suggest that Golgi-associated
glycosyltransferases diverged relatively early in evolution.
In the present study, we could detect dIGnT activity in the IGnT cloned
(23), as shown in Fig. 4, although the previous studies detected only
cIGnT activity (34). This discrepancy is probably attributable to the
fact that the chimeric soluble IGnT was assayed after concentration of
the culture supernatant in the present study, whereas a culture
supernatant was directly used in the previous study (34). These
results, as a whole, indicate that in vitro assay of
glycosyltransferase is a very powerful tool for detecting activity. On
the other hand, the expression of I antigen by C2GnT-M, assessed by
immunofluorescent staining was apparently as much as the I antigen
expressed by IGnT when the full-length cDNAs were expressed in CHO
cells (Fig. 3). This is strikingly in contrast to the results that
C2GnT-M had only 7% activity of dIGnT compared with C2GnT activity
when measured by in vitro assay (Fig. 4). These results
suggest that the enzymatic activities measured by in vitro
assay may not quantitatively reflect its actual activities in cells. It
is possible that the protein A portion of the chimeric protein may
bring a constraint on its catalytic domain. Future studies will be
important to determine how C2GnT-M synthesizes these different
oligosaccharides in a given cell.
-1,6-N-acetylglucosaminyltransferase-leukocyte type (C2GnT-L), is highly homologous to the I branching
-1,6-N-acetylglucosaminyltransferase (IGnT)
(Bierhuizen, M. F. A., Mattei, M.-G., and Fukuda,
M. (1993) Genes Dev. 7, 468-478). Using these
homologous sequences as probes, we identified an expressed sequence tag
in dbEST, which has significant homology to C2GnT-L and IGnT. This
approach, together with 5'and 3' rapid amplification of cDNA ends,
yielded a human cDNA that encompasses a whole coding region of an
enzyme, termed C2GnT-mucin type (C2GnT-M). C2GnT-M has 48.2 and 33.8%
identity with C2GnT-L and IGnT at the amino acid levels. The expression
of C2GnT-M cDNA directed the expression of core 2 branched
oligosaccharides and I antigen on the cell surface. Moreover, a soluble
chimeric C2GnT-M had core 4 branching activity in addition to core 2 and I branching activities. A soluble chimeric C2GnT-L, in
contrast, almost exclusively contains core 2 branching activity.
Northern blot analysis demonstrated that the C2GnT-M transcripts are
heavily expressed in colon, small intestine, trachea, and stomach,
where mucin is produced. In contrast, the transcripts of C2GnT-L were
more widely detected, including the lymph node and bone marrow. These
results indicate that the newly cloned C2GnT-M plays a critical role in
O-glycan synthesis in mucins and might have distinctly
different roles in oligosaccharide ligand formation compared with
C2GnT-L.
INTRODUCTION
Top
Abstract
Introduction
References
1
3GalNAc, is the major constituent of
O-glycans. Core 1 oligosaccharides are converted to core 2 oligosaccharides Gal
1
3(GlcNAc
1
6)GalNAc when core 2
-1,6-N-acetylglucosaminyltransferase (C2GnT)1 is present (3, 4).
Various ligand carbohydrates can be formed in core 2 branched
oligosaccharides. For example, sialyl Lex in mucin-type
glycoproteins of blood cells can be formed only in core 2 branched
oligosaccharides such as
NeuNAc
2
3Gal
1
4(Fuc
1
3) GlcNAc
1
6(NeuNAc
2
3Gal
1
3)GalNAc
serine/ threonine
(3, 5-7).
1
4GlcNAc
1
3)n can be converted to
branched poly-N-acetyllactosamine,
Gal
1
4GlcNAc
1
3 (Gal
1
4GlcNAc
1
6)Gal
R, by the
I branching enzyme IGnT (13, 14). These linear and branched
poly-N-acetyllactosamines represent, respectively, the i and
I antigens, which are expressed in a cell type-specific manner (1). It
has been shown that there exist two IGnTs, which use two different sets
of acceptor substrates (15-17).
1
3GalNAc, can be frequently found. These tissues also contain core 4, Gal
1
4GlcNAc
1
6(GlcNAc
1
3)GalNAc,
which was originally discovered in sheep gastric mucosa (18). Core 4 is formed from core 3 by core 4
-1,6-N-acetylglucosaminyltransferase (C4GnT). It has been
reported that the amount of core 4 oligosaccharides is reduced in
colonic carcinoma cells, whereas the amount of core 2 oligosaccharides
is maintained or increased (19, 20). More recently, the increase in the
transcript of C2GnT was found to be associated with the progression of
colonic carcinomas (21).
EXPERIMENTAL PROCEDURES
) vector, resulting in pcDNA3.1-C2GnT-M.
-lactone, 10 mM EDTA, 1 mM UDP-GlcNAc
containing 0.5 µCi of UDP-[3H]GlcNAc, and 20 µl of
the enzyme solution in total of 50 µl of 50 mM
4-morpholineethanesulfonic acid, pH 7.0. After incubation at 37 °C
for 1 h, the reaction was stopped by diluting with 1 ml of water,
and reaction products were purified by a C18 reversed-phase column
(Alltech) as described previously (27).
1
3GalNAc
pNP and GlcNAc
1
3GalNAc
pNP (Toronto Research Chemicals) were used for
assaying C2GnT and C4GnT activity, respectively.
Gal
1
4GlcNAc
1
3Gal
1
4GlcNAc
1
6Man
1
6Man
octyl, and
GlcNAc
1
3Gal
1
4GlcNAc
1
6Man
1
Man
1
octyl
were used for assaying IGnT activity. Because addition of
N-acetylglucosamine takes place at the underlined galactose
residues, the two acceptors serve for centrally acting IGnT
(cIGnT) and predistally acting IGnT (dIGnT), respectively
(17). The octyl compounds were synthesized as described previously (27)
and kindly provided by Drs. Joseph McAuliffe and Ole Hindsgaul of our institute.
-leukosialin (30) and the above vector
encoding the glycosyltransferase, because T305 reacts with core 2 oligosaccharides expressed in leukosialin (22, 30).
219-495) of C2GnT-L or by PCR
(nucleotides 1-577 of C2GnT-M) using C2GnT-M cDNA as a template.
RESULTS
-1,6-N-acetylglucosaminyltransferase gene family (23). By
searching the EST data base for identifying a novel cDNA related to
C2GnT and/or IGnT, one cDNA sequence was found to be highly
homologous to one of these shared regions (A region, see below).
Because this novel cDNA was isolated from human colon cancer cells,
we thought that the encoded enzyme may be involved in mucin
oligosaccharide synthesis. To obtain a full-length cDNA, 5' and 3'
RACE reactions were performed. Finally, the full-length cDNA was
prepared by reverse transcription-PCR of poly(A)+ RNA from
HT-29 colonic carcinoma cells.
View larger version (56K):
[in a new window]
Fig. 1.
Nucleotide and translated amino acid
sequences of C2GnT-M. The signal/membrane-spanning domain is
denoted by a dotted line. A consensus sequence for
polyadenylation signal is underlined, and potential
N-glycosylation sites are marked with
asterisks.
View larger version (64K):
[in a new window]
Fig. 2.
Homology among C2GnT-M, C2GnT-L, and
IGnT. The amino acid residues are numbered with respect to the
translation initiation methionine. Identical residues are indicated by
boxes. The regions with significant identity
(A-C) are shown by bold underlines. The regions
A-C are designated after comparison of all three proteins
using a Clustal program. Dots denote gaps in the
sequence.
View larger version (38K):
[in a new window]
Fig. 3.
Immunofluorescent staining of transfected CHO
cells by T305 or anti-I antibody. CHO cells were transfected with
pcDNAI-C2GnT-L (C2GnT-L), pcDNA3.1-C2GnT-M
(C2GnT-M), or pcDNAI-IGnT (IGnT) and then
incubated with T305 monoclonal antibody or anti-I human serum followed
by fluorescein isothiocyanate-conjugated goat-anti-mouse IgG (for T305)
or anti-human IgM (for anti-I serum). For T305 staining, the cells were
co-transfected with pcDSR -leukosialin and cDNA encoding the
glycosyltransferases. Bar, 40 µm.
1
3GalNAc
pNP and a
barely detectable amount of activity toward
GlcNAc
1
3GalNAc
pNP. As expected, C2GnT-L did not show any
activity toward acceptors for IGnT. C2GnT-M, in contrast, exhibited a
substantial activity also to GlcNAc
1
3GalNAc
pNP, indicating
that C2GnT-M exhibits C4GnT activity as well. Interestingly, I
branching enzyme activity of C2GnT-M was detected more as a dIGnT than
a cIGnT (Fig. 4B). These results indicate that the newly
cloned C2GnT-M has a weak but detectable activity of IGnT in addition
to C2GnT and C4GnT activities.
View larger version (12K):
[in a new window]
Fig. 4.
Incorporation of 3H-GlcNAc from
UDP-[3H]GlcNAc to acceptors by C2GnT-L (A),
C2GnT-M (B), and IGnT (C). The soluble
chimeric enzyme in the spent medium (A and C) and
that bound to IgG-Sepharose (B) were assayed for C2GnT,
C4GnT, dIGnT, and cIGnT activities. The highest activities of C2GnT-L,
C2GnT-M, and IGnT were 30 nmol/h/ml (for C2GnT activity), 130 pmol/h/ml
(for C2GnT activity), and 894 pmol/h/ml (for cIGnT activity),
respectively, and they were taken as 100%. S.E.s are shown by
bars.
View larger version (59K):
[in a new window]
Fig. 5.
Northern blot analysis of C2GnT-M and
C2GnT-L. Each lane contained 2 µg of
poly(A)+RNA. The blots were hybridized with
32P-labeled C2GnT-M cDNA followed by
32P-labeled C2GnT-L cDNA. Each blot contained seven or
eight lanes and was run separately. The migration positions of
molecular markers are the same in the two blots shown at
right.
DISCUSSION
-2,3-sialyltransferase, were shown to add, respectively, fucose and
sialic acid residues to both Gal
1
4GlcNAc and Gal
1
3 GlcNAc
acceptors (35-37). As far as we know, we are the first to demonstrate
in a definitive manner that a single enzyme catalyzes three different
but related reactions.
1
3
Gal
1
4 GlcNAc
1
R, forming
GlcNAc
1
3(GlcNAc
1
6)Gal
1
4GlcNAc
1
R.
Although the presence of this enzyme activity, dIGnT, was reported
previously (14-17), a cDNA encoding an enzyme acting more as a
dIGnT than as a cIGnT was not reported before. The activities of dIGnT
reported in hog gastric mucosa and rat liver (14, 17) may be
attributable to the newly cloned C2GnT-M. However, those enzymatic
activities reported previously had much less C2GnT or C4GnT activity
compared with dIGnT activity, whereas the opposite is true for C2GnT-M. It is thus likely that both IGnT and C2GnT-M contribute to dIGnT activity in these tissues. Our cloned enzyme most closely resembles the
C2GnT preparation isolated from bovine trachea (16). However, dIGnT activity of the bovine trachea enzyme preparation was almost 40% of its C2GnT activity, whereas it is only 7% of C2GnT
activity in the cloned C2GnT-M, although similar acceptors were used in both studies. On the other hand, it is noteworthy that the ratio of
C2GnT and dIGnT activities in LS180, HT29, and NCI498 colonic carcinomas (20) is similar to that of C2GnT-M. Further studies are necessary to clarify this discrepancy.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Drs. Kiyohiko Angata, Minoru Ujita,
and Shigeru Tsuboi for providing pcDNA3-A, pcDNAI-A·IGnT and
pcDNAI-A·C2GnT, and pcDSR-leukosialin, respectively, Drs.
Joseph McAuliffe and Ole Hindsgaul for the synthetic oligosaccharides,
Dr. Michiko Fukuda for useful discussion, and Susan Greaney for
organizing the manuscript.
![]() |
FOOTNOTES |
---|
* This work was supported by MERIT Award R37 CA33000 and in part by Grant PO1 CA71932 from the NCI, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF102542.
To whom correspondence should be addressed: Burnham Institute,
10901 North Torrey Pines Rd., La Jolla, CA 92037. Tel.: 619-646-3144; Fax: 619-646-3193; E-mail: minoru{at}burnham-inst.org
The abbreviations used are:
C2GnT-L and -M, core
2 -1,6-N-acetylglucosaminyltransferase-leukocyte type and
-mucin type, respectively; dIGnT and cIGnT, distally acting and
centrally acting I branching
-1,6-N-acetylglucosaminyltransferase, respectively; C4GnT, core 4
-1,6-N-acetylglucosaminyltransferase; EST, expressed sequence tag; PCR, polymerase chain reaction; RACE, rapid
amplification of cDNA ends; CHO, Chinese hamster ovary; pNP, p-nitrophenol; RH, radiation hybrid.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() |
---|